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Abstract
Genome wide association (GWA) studies have reproducibly identified signals on chromosome 4q24 associated with
lung function and COPD. GSTCD (Glutathione S-transferase C-terminal domain containing) represents a candidate
causal gene in this locus, however little is currently known about the function of this protein. We set out to further our
understanding of the role of GSTCD in cell functions and homeostasis using multiple molecular and cellular
approaches in airway relevant cells. Recombinant expression of human GSTCD in conjunction with a GST activity assay
did not identify any enzymatic activity for two GSTCD isoforms questioning the assignment of this protein to this family
of enzymes. Protein structure analyses identified a potential methyltransferase domain contained within GSTCD, with
these enzymes linked to cell viability and apoptosis. Targeted knockdown (siRNA) of GSTCD in bronchial epithelial cells
identified a role for GSTCD in cell viability as proliferation rates were not altered. To provide greater insight we
completed transcriptomic analyses on cells with GSTCD expression knocked down and identified several differentially
expressed genes including those implicated in airway biology; fibrosis e.g. TGFBR1 and inflammation e.g. IL6R. Pathway
based transcriptomic analyses identified an over-representation of genes related to adipogenesis which may suggest
additional functions for GSTCD. These findings identify potential additional functions for GSTCD in the context of
airway biology beyond the hypothesised GST activity and warrant further investigation.
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Background
Lung function forms a key diagnostic criteria for chronic
obstructive pulmonary disease (COPD), a leading cause
of morbidity and mortality. A greater understanding of
genetic variants associated with lung function and
COPD may provide new insight into disease mecha-
nisms and provide new opportunities for therapeutic
intervention. In 2010, two large consortia for respiratory
research: SpiroMeta consortium (n = 20,288 individuals
of European ancestry) and Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) consor-
tium (n = 21,209 individuals of European ancestry) con-
ducted the first in a series of meta-analyses of GWA
studies which identified a selection of loci associated
with lung function, the most significant of which were
novel variants at locus 4q24 [1, 2].
Later studies suggested two independent signals in this
region [3, 4] including variants at the GSTCD and the
NPNT gene. Importantly, the genetic effects appear to
be independent of both smoking and disease status [2].
More recent studies replicated association with variants
spanning GSTCD and forced expiratory volume in one
second (FEV1), forced vital capacity (FVC) and COPD
[5–12]. Furthermore, these variants have recently been
associated with FEV1 in children and with growth, mea-
sured as bronchial responsiveness development [13],
thus suggesting that GSTCD may have an early life ef-
fect. Therefore, GSTCD represents a potential candi-
date/casual gene in this region and may functionally
contribute to the development or severity of COPD.
In our previous work we demonstrated that GSTCD
mRNA is expressed in multiple airway relevant cell types
and total lung mRNA expression of GSTCD correlated
with lung function [14]. GSTCD protein expression
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decreased between the pseudoglandular and canalicular
stages in human lung suggesting a potential role in de-
velopment. Little is known about the function of GSTCD
in cells and tissues and based on homology it has been
designated a potential member of the Glutathione S-
Transferase (GST) family of enzymes due to a shared C-
terminal α-helical domain [2]. GST enzymes carry out cel-
lular detoxification, by conjugating glutathione to a variety
of endogenous targets [15]. The function of GSTCD par-
ticularly in airway cells remain to be determined.
To elucidate the role of GSTCD in cell function and
homeostasis we used multiple approaches including; re-
combinant expression (gain of function) combined with
GST activity assessment to define the activity of GSTCD.
Similarly, to test the hypothesis that GSTCD is required
for normal cell homeostasis we used targeted knock-
down (loss of function) in primary human airway epithe-
lium followed by analyses of proliferation, apoptosis and
Reactive Oxygen Species (ROS) quantification. Import-
antly, in parallel we used a hypothesis free approach to
identify functions of GSTCD by examining global tran-
scriptomic changes in human bronchial epithelial cells
(HBECs) with targeted knockdown of GSTCD.
Overall, we demonstrate that GSTCD does not have
GST activity suggesting yet undiscovered functions of this
uncharacterized protein. Our findings using multiple ap-
proaches suggests a role in primary human cell homeosta-
sis influencing cell viability including also a regulatory
function influencing several genes related to airway biol-
ogy e.g. Transforming growth factor β (TGFB) and Inter-
leukin 6 (IL6) signalling and genes related to adipogenesis.
Methods
GST activity assay
The SensoLyte® GST Activity Assay Kit (AnaSpec) was
used to determine the GST activity of cell hosts; CHO-K1,
Human airway smooth muscle (HASM) and human bron-
chial epithelial (HBEC) cells engineered to express
GSTCD or GSTM5 (positive control) in 96 well plate for-
mat as described by the manufacturer. Cells were main-
tained in culture as previously described; CHO-K1 [16],
HASM [17], HBEC [18]. Briefly, cells were transfected
with plasmids pIRES-GSTCDT1, pIRES-GSTCDT2 (two
isoforms of GSTCD, variant 1 NP_001026890.2 and
GSTCD variant 2 NP_079027.2 where variant 2 contains a
truncated exon 2 leading to an 87amino acid shorter pro-
tein), pIRES-Empty Vector (EV, negative control) or
pcDNA-GSTM5 (positive control) as described [19] and
after 48 h transfection the enzymatic reaction was mea-
sured on a Flexstation®3 (Molecular Devices).
Protein prediction modelling of GSTCD
Three protein prediction servers (I-TASSER, SWISS-
MODEL and Phyre2). These structure modelling servers
were integrated for homology for both GSTCD variants;
NP_001026890.2 and NP_079027.2 with proteins of
known structure and function. Three primary template
based protein structure modelling servers were employed
to infer potential 3D protein structures and function of
GSTCD based on sequence homology [20] (Iterative
Threading Assembly Refinement (I-TASSER) (threading
method), SWISS-MODEL and Phyre2 (comparative mod-
elling methods)). Sequences for both published human
GSTCD protein variant sequences (NCBI references:
GSTCD variant 1 NP_001026890.2 and GSTCD variant 2
NP_079027.2) were input into the servers and analysed by
comparing results from the different protein prediction
servers alongside results for the positive control Glutathi-
one S-transferase Mu 5 (NCBI reference: NP_000842.2).
GSTCD SiRNA experiments
HBECs were grown as described [18] and knockdown of
GSTCD was achieved by transfection with siRNAs as de-
scribed [21]. Three pre-designed sequences (A, B and C)
targeted to different regions of the GSTCD gene (ORI-
GENE SR312613) were used to reduce expression of
GSTCD and a scrambled control siRNA sequence was
included for reference. Optimisation of the siRNA con-
centration transfected into HBECs using INTERFERin®
transfection reagent (Polyplus Transfection, 409–10),
was carried out using 0.1 nM, 1 nM and 10 nM for each
individual SiRNA A, B, or C and a combination of all 3
for 48 h prior to assessing GSTCD mRNA levels using
qPCR. Two of the 3 siRNAs were chosen to take for-
ward (to provide confidence and account for off target
effects) and a time course (12, 24, 48 and 72 h) was used
to optimise the reduction in GSTCD mRNA. Two of the
3 siRNAs were chosen to take forward (to provide confi-
dence and account for off target effects) at a concentration
of 1 nM siRNA. Forty-Eight hours post transfection RNA
for Taqman and protein for Western blotting was ex-
tracted from these cells as described below. The GSTCD
Pre-Developed TaqMan® Assay Reagent (PDAR) was
chosen across Exons 5 and 6 of GSTCD and an 18S PDAR
was used as the housekeeping control for Taqman.
Cell experiments were set up in 6 well culture plates.
At the specified time points cells were either used for
RNA or protein extraction by the following methods.
The GenElute RNA extraction kit (Sigma) lysis solution
was prepared according to protocol with the addition of
Beta-Mercaptoethanol. Two wells of a six well plate per
condition were washed in ice cold PBS followed by the
addition of 600ul lysis solution, cells were scraped off and
transferred into an Eppendorf. This was frozen at -80 °C
until the RNA extraction was carried out at a later date.
The protein lysis extraction buffer was made up of 1.5
ml unsupplemented cytobuster (cytobuster is one tablet
dissolved in 10 ml of cytobuster liquid), 15ul Benzone
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Nuclease, 1.5ul Dithiothreitol and 3ul Pepstatin A. Cells
were washed in ice cold phosphate buffered saline and
200ul of protein lysis buffer was added into one well be-
fore cells were scraped off the plastic and this was then
transferred into a second well of cells for lysis. This was
then placed in an Eppendorf and frozen at -80 °C until
the protein was used for quantification and Western
blotting. Two polyclonal primary antibodies against
GSTCD were used at dilutions of 1:500 and 1:1000 (Pro-
teintech, 17,502–1-AP and Abnova, H00079807-B01)
with β-actin antibody (Abcam, ab8227) diluted 1:5000
used as a control in the Western blotting.
Cell proliferation, number and apoptosis assays
After GSTCD siRNA knockdown in HBECs the cell prolif-
eration rate, total cell number and apoptosis were quanti-
fied at different time intervals using the CyQUANT® NF
proliferation assay, Click-iT® EdU microplate assay and
Apoptosis was measured using the In situ cell death detec-
tion kit (Roche).
The CyQUANT® NF proliferation assay measures total
cell number utilising a cell permeable fluorescent DNA
binding dye applied to the cells at the experimental end-
point. Click-iT® EdU microplate assay labels actively pro-
liferating cells by incorporating the thymidine analogue
5-ethynyl-2-deoxyuridine (EdU) into DNA during cell
replication, followed by antibody based signal amplifica-
tion resulting in a fluorescence reading. Apoptosis was
measured using the In situ cell death detection kit
(Roche). In this assay the green fluorescent is an indica-
tor of broken down DNA strands. The HBECs were
seeded on 8-well chamber slides and transfected with
the siRNA as previously described, cells were then fixed
and the ratio of green apoptotic cells to the total number
of blue DAPI stained cells were compared.
RNA sequencing
RNA integrity (RIN) analysis was carried out on the Agi-
lent 2100 Bioanalyser to check quality (RIN > 9). Library
preparation and sequencing was performed by Deep Seq,
University of Nottingham. Paired end sequencing was per-
formed using the Illumina NextSeq500 and generated 60
million paired end reads (75 bp) for each sample. Analyses
of the RNA-seq data used the previously developed pipe-
line [21] described briefly here. Trimmed reads were
aligned to the reference genome (human genome hg19)
using TopHat v2.0.12 [22] adapter trimming was achieved
using Scythe© (https://github.com/vsbuffalo/scythe) and
“Quality Trimming” was performed using Sickle (https://
github.com/najoshi/sickle). Reads underwent quality con-
trol analysis before and after trimming using FastQC©
v0.10.1 (Simon Andrews, Babraham Bioinformatics). Dif-
ferential Gene Expression Analysis was performed using
the Cufflinks suite [22]. Briefly, alignment files were run
through Cufflinks for transcriptome assembly. The as-
semblies were merged using Cuffmerge. Differential
expression by Cuffdiff with a false discovery rate
(FDR) of 5%. The inclusion of two siRNA targeting
GSTCD provided an initial filter of results and we fo-
cussed to genes showing differential expression in
both siRNA. Finally to provide greater robustness to
the RNA-seq differential expression analysis we added
a series of further filters including continuity in frag-
ments Per Kilobase of transcript per Million mapped
reads (FPKM) values across triplicates, which left
genes significantly altered in the GSTCD knockdown
compared to the scrambled control levels of expres-
sion only.
Gene set enrichment pathway analysis
Using the Gene set Enrichment Analysis (GSEA) from
the Molecular signatures database we used the Curated
gene set (C2) comprising 4738 gene sets and the Hall-
mark gene set (H) comprising 50 pathways. An FDR of
25% (FDR q = 0.25) indicates that the result is likely to
be valid 3 out of 4 times, which is reasonable in the set-
ting of exploratory discovery where one is interested in
finding candidate hypothesis to be further validated as a
results of future research [23, 24].
Reactive oxygen species (ROS) assay
The Oxiselect™ In Vitro ROS Assay Kit (Life Technolo-
gies) was used to measure the total free radical activity
in supernatants taken from the GSTCD siRNA trans-
fected HBEC experiments. Supernatants were plated in
triplicate in 96 well plates and mixed with a catalyst to
accelerate the oxidative reaction. A fluorescent probe
(DCF-DiOxyQ) was added and the plate analysed on a
Flexstation®3, the free radical content is determined by
using a standard curve. The experiment was carried out
on both fresh and frozen supernatants and fresh homo-
genised cells.
Statistical analysis
Data were analysed using GraphPad Prism 6 software
(GraphPad Software, Inc.). The Kruskal-Wallis statistic
was performed and median and inter-quartile range shown
on the graphs. RNA seq differential Gene Expression Ana-
lysis was performed using the Cufflinks suite [22]. For all
statistical analysis described above, a p-value of <0.05 was
considered to be significant.
Results
GSTCD does not demonstrate classical GST activity
We expressed recombinant GSTCD in a number of cell
hosts including CHO-K1, HASM and HBEC to determine
if the GSTCD protein had GST activity. Two vectors ex-
pressing different isoforms of human GSTCD were
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transfected into two human airway cell types: airway
smooth muscle (HASM) and bronchial epithelial cells
(HBECs) alongside transfection of the positive control
GST Mu5 (GSTM5). CHO-K1 which have endogenous
GST activity was also transfected with the GSTCD plas-
mids. The two GSTCD isoforms differ in exon 2 (variant 2
is truncated) resulting in proteins of 633 amino acids and
546 amino acids respectively for variant 1 and 2 [14]. The
Sensolyte GST activity assay was performed on these recom-
binant cells, results revealed no discernible change in GST
activity in either GSTCD variant 1 or 2 cells (relative to
empty vector and transfection reagent only negative con-
trols) (Fig. 1). In contrast, recombinant GSTM5 cells, a well
characterised GST enzyme resulted in 2–3 fold increased
GST activity relative to the negative controls (p= 0.02 in
HASM). Based on these data the two reported protein iso-
forms of GSTCD do not have atypical GST activity in three
independent cell hosts.
GSTCD protein structure prediction and nucleotide
homology searches suggest additional protein functions
To address the lack of information regarding potential
GSTCD function, homologous protein sequences were
sought using three protein prediction servers I-TASSER,
SWISS-MODEL and Phyre2. Homologous matches to
the GSTCD protein sequence were searched with results
indicating a high homology to methyltransferase en-
zymes across the servers (Table 1). Sequence homology
is predominantly located across the predicted methyl-
transferase domain (variant 1: 423-541aa and variant 2:
336-454aa) as opposed to the GST C-terminal α-helical
domain (variant 1: 251-332aa and variant 2: 164-245aa)
and this is consistent throughout the top homologous
matches for each server. Therefore these data provide
initial insight that GSTCD may have additional protein
functions, with methyltransferase enzymes linked to cell
viability and apoptosis.
Targeting GSTCD by RNAi significantly attenuates both
mRNA and protein expression in primary bronchial
epithelial cells
To begin to understand the role of GSTCD in the cell we
optimised GSTCD knock down in HBEC using the siRNA
technique. Optimal conditions for maximal knock down
were 1 nM siRNA incubated for 48 h and resulted in 88%
(siRNA B) and 90% (C) decrease in GSTCD mRNA (Fig. 2),
with 86% (siRNA A, data not shown). SiRNA B and C were
taken forward in further experiments to help distinguish
between true and off target effects.
Semi-quantified Western blotting focussed to experi-
ments using the siRNA B and C demonstrated GSTCD
expression was reduced by 63% (siRNA B) and 74%
(siRNA C) relative to untransfected control lysates (siRNA
B p < 0.0036 and C p < 0.036, Kruskal Wallis. Figure 2).
Therefore, both siRNA B and siRNA C effectively reduced
GSTCD mRNA and protein expression in HBECs provid-
ing a platform for functional analyses.
Targeted GSTCD knock down does not influence cell
proliferation but is associated with reduced numbers of
bronchial epithelial cells when cultured over 72 h
To assess potential effects of GSTCD knock-down on cell
growth two assays were utilised to investigate actively prolif-
erating cells (Click-iT® EdU assay) and total cell number
(CyQUANT® NF assay). GSTCD expression was knocked-
down in HBECs as previously described over a 24, 48 and
72 h. No discernible changes in levels of actively proliferat-
ing cells were observed in either siRNA GSTCD knock-
down sample relative to untransfected or scrambled controls
(Fig. 3a). However total cell number was reduced in both
siRNA B and C across time relative to untransfected or
scrambled siRNA treated hBECs, with siRNA C displaying
the greatest magnitude of effect (Fig. 3b). At 72 h total cell
number was significantly reduced compared to scrambled
Fig. 1 Recombinant expression of GSTCD in multiple cell types does not identify GST activity Levels of GST activity are determined through
fluorescence measurements (mU/ml) and expression is shown relative to EV. Graphs show median and interquartile range data analysed using
Kruskal-Wallis test. a GST activity in CHO-K1 cells stably transfected with GSTCD variant 1 (T1), GSTCD variant 2 (T2) or empty vector (EV) showing
no increased activity above the EV control (n = 4). b HASM cells transiently transfected with EV control, T1, T2, GSTM5 positive control (M5) and
transfection reagent only (TRO). The relative GST activity was shown to be significant between the EV and M5 (p = 0.002,) however the two
isoforms of GSTCD did not show any increased GST activity (n = 4). c HBEC cells transliently transfected with the plasmids showed no significant
increases in GST activity over the EV (n = 4)
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siRNA for siRNA C (p < 0.02) when results are normalised
to untransfected cells.
Targeted GSTCD knockdown does not have any impacts
on apoptosis rate in bronchial epithelial cells
We wanted to determine if the reduction in total cell
number observed in the human cell system could be ex-
plained by increased apoptosis in the GSTCD knockout
cells. Figure 4 shows that there is no statistically signifi-
cant difference in apoptosis levels between cells with
GSTCD knocked down and the untransfected, transfec-
tion reagent alone or scrambled siRNA treated cells.
There was a trend toward increase in apoptosis in
siRNA B > siRNA C which inversely correlates with the
effects of these siRNA on cell numbers. However, overall
these data suggest decreased GSTCD expression has no
significant effect on apoptosis in airway epithelial cells.
Targeted GSTCD knockdown in combination with
transcriptomics identifies novel potential functions in
bronchial epithelial cells
In order to identify novel functions of GSTCD in the cells
and new understanding we completed a series of tran-
scriptomic experiments using bronchial epithelial cells
with GSTCD targeted knockdown. The RNA-seq profiling
gave over 50 million aligned paired reads per sample to
the hg19 genome build. A FDR of 5% was applied which
identified 41 genes showed significant differential mRNA
expression levels following GSTCD knockdown using ei-
ther siRNA B or siRNA C compared with scrambled and
untransfected gene expression providing an initial focus
(Fig. 5). Further refinement of differentially expressed
genes to reproducible effects across each biological repli-
cate identified 17 priority genes altered transcription post
GSTCD knockdown compared to the scrambled control
levels (Table 2).
Reassuringly, GSTCD was the most significantly re-
duced mRNA, then the gene with the next greatest mag-
nitude of change was; Lymphocyte cytosolic protein 1
(LCP1) with a 27 and 17 fold induction in mRNA in
siRNA B and C respectively. In this modest number of
genes identified several have been previously associated
with airway biology and disease including e.g. TGFBR1,
the receptor for TGFB1 involved in fibrosis and IL6R a
cytokine receptor implicated in airway disease e.g.
asthma. A description of these top 17 genes can be
found in Table 3. To provide further reassurance of our
findings we investigated the mRNA levels of three
Table 1 Protein structure prediction results for the two GSTCD isoforms using three models I-TASSER, SWISS- MODEL and Phyre2.
Methyltransferase (MTF) enzymes are frequently found in the top 3 structural templates listed for each server and the top 50
template results in SWISS-MODEL were entirely methyltransferase proteins, with specific focus on rRNA methyltransferase function.
Alternatively, I-TASSER identified homology in this region with transport receptors, specifically importin β subunit 1, involved in
transporting proteins into the nucleus [25]. Other top hits included: exodeoxyribonuclease (catalyses degradation of double stranded
DNA), Ras guanyl-releasing protein 1 (nucleotide exchange factor specifically activating Ras, activates the extracellular signal-
regulated kinases/mitogen-activated protein kinase (ERK/MAPK) cascade) and nicotinamide adenine dinucleotide binding (NADB)-
Rossmann fold superfamily protein (structural motif found in proteins that bind nucleotides)
Protein Structure
Results
I-TASSER SWISS-MODEL Phyre2
Variant 1 Variant 2 Variant 1 Variant 2 Variant 1 Variant 2
Predicted
Secondary
Structure
Primarily α-helices with intermittent
coil structures.
β-strands only present at termini.
N/A Primarily intermittent α-
helices (45%).
β-strands only present at
termini (12%).
Two predicted
transmembrane regions (30-
40aa and 281-299aa).
Primarily intermittent α-
helices (55%).
β-strands only present at
termini (10%).
Two predicted
transmembrane regions (29-
38aa and 194-212aa).
Regions of
Primary
Sequence
Homology
Primarily across the MTF domain to
C-terminus.
Partial matches across whole
protein.
Only across the MTF
domain to C-terminus
Only across the MTF domain
Intrinsic disorder N/A Low disorder
across C-
terminus
High
disorder
across C-
terminus
Two theoretical central
regions of disorder (27%):•
204-270aa• 325-386aa
Two theoretical central
regions of disorder (26%):•
118-184aa• 257-299aa
Top 3 Structural
Templates
Putative MTF
Importin β subunit
Exodeoxyribonuclease
Ras guanyl-
releasing
protein 1
MTF
Protein
RdmB MTF
Protein
RdmB MTF
Protein
RdmB MTF
Putative
rRNA
methylase
Putative
rRNA
methylase
rRNA small
subunit MTF
rRNA small subunit MTF
Transferase
S-adenosyl-L-methionine-
dependent MTF
Transferase
NADB-Rossmann fold
superfamily protein
S-adenosyl-L-methionine-
dependent MTF
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Fig. 2 GSTCD can effectively be targeted in vitro leading to a reduction in mRNA and protein levels. a. Shows RNA expression using taqman
normalised to the untransfected condition. Both SiRNA B and C knocked down the GSTCD RNA to a similar extent. b. Western blots to show the
GSTCD protein levels (71 kDa) are reduced in hBEC lysates following siRNA knock-down. GSTCD protein levels were noticeably reduced relative to
untransfected and scrambled controls for each siRNA in all samples (n = 3). c. Semi-quantification of GSTCD protein levels by densitometry.
Proportional changes are shown with results normalised against untransfected control. GSTCD protein expression is significantly reduced for
siRNA B (p < 0.0036) and siRNA C (p < 0.036) using Kruskal Wallis test showing median and interquartile range. N = 3 independent experiments
Fig. 3 GSTCD siRNA knock-down in hBECs results in reduced total cell number while not influencing proliferation. GSTCD siRNA knock-down in
hBECs does not affect proliferation rate (Click-iT® EdU) but does result in reduced total cell number over 72 h (CyQuant) in cell culture. Graphs
show median and interquartile range data analysed using Kruskal-Wallis test. a. The Click-iT® EdU assay data is normalised to Untransfected
controls (100%) bar. No change in proliferation rate was seen in GSTCD knock-down samples (siRNA B and C) relative to untransfected or
scrambled controls at any time-point. b. The CyQuant assay shows a noticeably reduced total cell number in both GSTCD knock-down samples,
with an increasing effect across the time-course and significant reduction evident at 72 h compared to scrambled for siRNA C (p = 0.02).
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abundant mRNA in the original HBEC donor used for
RNA seq analysis and also in a second independent
donor. The three genes selected were; GPR176, C12orf49
and ETS1 (Fig. 6). In the original donor used for the
RNA seq experiments taqman significantly confirmed
knockdown of expression in GPR176 and ETS1 (p =
0.0087 and p = 0.0016 respectively Kruskal-Wallis) but
was not significant for the C12orf49 gene expression. In
the second donor none of these genes showed a significant
differential gene expression although the GSTCD expres-
sion by taqman was significant for both donor1 and
donor2 (p = 0.009 and p = 0.008 respectively). This lack of
replication in the second donor may be due to the in-
creased heterogeneity observed in this dataset.
Pathway based analyses of transcriptomic data implicate
a role for GSTCD in multiple pathways including;
oxidative phosphorylation/reactive oxygen species
pathways and adipogenesis
Using the Gene set Enrichment Analysis (GSEA) from
the Molecular signatures database we searched the Cu-
rated gene set (C2) and the Hallmark gene set (H)
pathways. These analyses identified 29 significantly up-
regulated pathways which were mainly Cancer focussed
but also Adipogenesis related and a Reactive Oxygen
species (ROS) pathway involved in insulin resistance.
Eight pathways were significantly upregulated in the H
Fig. 4 GSTCD siRNA knock-down in hBECs does not influence cell apoptosis. The ratio between the Apoptosis assay (Apo-ONE) and the total cell
number assay (CyQuant) was used to determine the level of apoptosis in the GSTCD siRNA knock-down conditions taking into account any cell
number variability. GSTCD knock down did not influence the level of apoptosis when corrected for cell number in these experiments. TRO,
transfection reagent only. No significance using Kruskal Wallis test showing median and interquartile range (n = 4)
Fig. 5 Venn diagram illustrating the number of genes differentially
expressed following GSTCD knockdown for the indicated conditions.
The GSTCD knock down gene expression profile was compared with
the scrambled and shows 41 genes to be reproducibly changed in
both siRNA B and C and not confounded by differences between
control conditions untransfected/scrambled
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pathway analysis and no pathway showed any signifi-
cant downregulation at this 25% FDR (q-value < 0.25)
significance level. Table 4 shows results from the H
pathway analysis with the number of genes in each
pathway and the percent of those genes upregulated in
the knockdown cells. Adipogenesis and ROS pathways
were significantly upregulated (FDR 25%).
GSTCD knockdown and ROS handling in bronchial
epithelial cells in vitro
Based on the initial observation that the reactive oxygen
species pathway is upregulated in human bronchial epi-
thelial cells with targeted GSTCD based on RNA-seq
data we wanted establish whether this knockdown could
alter the ROS activity. To do this we used the Oxiselect™
ROS activity assay. Supernatants from fresh, frozen and
directly from cells homogenised after 48 h transfection
with the GSTCD siRNA were analysed (Fig. 7, no statis-
tics were performed as it was n = 1 for each condition).
There was no difference in ROS activity in either the cell
supernatants or the cell homogenates from cells with or
without GSTCD knockdown.
Discussion
We set out to further our basic understanding of the still
largely uncharacterised protein, GSTCD in the context
of a potential role in the airways as genetic variants
spanning GSTCD have reproducibly been associated
with lung function and COPD in multiple GWAS. To
achieve this, we used overlapping and complementary
approaches including producing the recombinant pro-
tein, targeting GSTCD by siRNA followed by cell biology
outcomes and transcriptomic analyses to identify novel
functions. Overall we demonstrate that GSTCD does not
have measurable GST activity suggesting additional un-
identified protein functions, that GSTCD is required for
cell homeostasis with reduction of the protein level asso-
ciated with reduced cell numbers in vitro. Finally, we
show that targeting GSTCD expression has a robust ef-
fect on a modest number of genes including genes that
may influence airway cell biology e.g. TGFB1 and IL6
signalling and the more novel finding of a role in adipo-
genesis. These data provide additional insight into the
role of GSTCD in the cell and highlights potential func-
tions in the context of respiratory disease warranting
further investigation.
The predicted GST function of GSTCD in part contrib-
uted to initial interest in this gene as a candidate/causal
gene underlying the association signal with lung function
on chromosome 4 as GST enzymes have a detoxification
role in the airways [38]. However, investigation of classical
GST activity in a GSTCD over-expression system revealed
no change in GST activity whereas over-expression of
GSTM5 resulted in 2–3 times increased GST expression
relative to the negative controls. This finding is intriguing
and while we acknowledge the limitation of our study that
we did not assess all GST activity, suggests that the assign-
ment of protein family based on initial homology may be
in error. Interestingly, GSTCD appears to have only one
of the two domains characteristic of the GST family of
Table 2 Shows the list of 17 genes with significant differential expression after GSTCD knockdown with an FDR less than 5% from
RNA seq analysis. The * denotes those genes with an expression level similar or higher than GSTCD expression
Gene Direction of Effect SCR vs B log2(fold_change) SCR vs B q_value SCR vs C log2(fold_change) SCR vs C q_value
GSTCD – 2.50688 0.00625 2.60049 0.00306
AKAP12* – 2.06957 0.00625 1.45912 0.00306
C12orf49* – 1.41126 0.00625 0.856333 0.00306
CUX2* – 1.30553 0.00625 0.831766 0.00306
DESI2* – 1.36908 0.00625 0.69109 0.00306
UHMK1* – 1.10051 0.00625 1.07772 0.00306
ST6GALNAC1* + 1.05294 0.00625 1.02191 0.00306
PPAP2C + 1.05893 0.00625 1.25417 0.00306
XLOC_020899 – 1.54684 0.00625 1.13877 0.01732
TGFBR1* – 0.86861 0.00625 0.552792 0.04536
GPD1L – 1.04006 0.01063 1.23236 0.00306
FAT2* + 0.761438 0.01451 1.045 0.00306
LCP1 – 1.42681 0.01451 1.239 0.03647
TSPAN7 + 1.14222 0.01451 0.915029 0.04412
ETS1* – 0.672957 0.03997 0.678173 0.01232
GPR176* – 0.864392 0.04704 0.694795 0.02858
IL6R* + 0.750533 0.04874 0.825264 0.00306
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enzymes [39] (C-terminal α-helical domain) and lacks the
N-terminal thioredoxin-type domain. Furthermore, gluta-
thione is thought to bind GST enzymes between the N-
and C-terminal domains, therefore indicating that both
domains are necessary for GST activity and that GSTCD
may simply have GST-like activity [39]. The more thor-
ough structural analyses completed in the current study
extends and complements our previous work that sug-
gested GSTCD shares similar motifs with methyltransfer-
ase enzymes, GST enzymes and Eukaryotic Elongation
Translation Factor 1 epsilon 1 (EEFE1/AIMP3); a com-
ponent of the aminoacyl tRNA synthase complex [14].
In the current study potential methyl transferase do-
main was highlighted and warrants further investiga-
tion. Methyltransferases have been implicated in cell
homeostasis including; e.g. histone methyltransferase
(NSD3) which has a role in cell viability and apoptosis
[40] and carboxyl methyltranferase acrivity modulates
endothelial cell apoptosis [41].
In order to formally assess the potential role of
GSTCD in cell homeostasis including cell viability and
apoptosis we developed siRNA targeted knockdown in
primary human bronchial epithelial cells. This approach
effectively reduces GSTCD expression at both the
mRNA and protein levels, hence this is a valuable
method to study effects of minimal GSTCD levels in a
human in vitro model. We then looked at cell prolifera-
tion and viability under these conditions. The results
suggest a possible role for GSTCD in determining cell
number when assessing total cell number which was sig-
nificantly reduced in cells targeted by GSTCD siRNA.
However when proliferation was assessed in parallel
these data do not indicate a role in cell proliferation for
GSTCD, instead potentially suggesting a role in cell via-
bility. To provide further insight we investigated the ef-
fect of targeting GSTCD on apoptosis in these cells.
Knockdown of GSTCD did lead to an increase in apop-
tosis in bronchial epithelial cells albeit this did not reach
Table 4 Summary table of the pathways significantly upregulated in the Hallmark GSEA. The FDR 25% was the significance level cut
off (FDR q < 0.25) only upregulated pathways were significant in both GSTCD SiRNA B and SiRNA C gene lists and there were no
significantly different pathways with an FDR below 10%
Upregulated Pathways Number of genes in pathway Number of Significant genes for B and C (%) B FDR q-val C FDR q-val
Adipogenesis 196 46 (23) 0.013 0.012
Bile Acid Metabolism 112 15 (13) 0.1 0.061
Estrogen Response early 199 34 (17) 0.16 0.00081
Fatty Acid Metabolism 158 24 (15) 0.16 0.045
Oxidative Phosporylation 199 62 (31) 0.037 0
P53 Pathway 199 46 (23) 0.1 0.0007
Peroxisome 103 29 (28) 0.2 0.038
Reactive Oxygen Species Pathway 47 12 (25) 0.1 0.061
Fig. 6 Quantitative PCR analysis of three genes which were differentially expressed after GSTCD knock down in RNA-seq analyses. The Taqman
was performed in two different donors, the original donor which RNAseq was performed (donor 1) and a second donor for comparison (donor
2). Untransfected set at 100% expression, red is GSTCD, green is GPR176, blue is C12orf49 and purple is ETS1. The 3 genes were chosen due to a
good level of expression before and after GSTCD knock down as well as being high on the RNAseq gene list so that the effect can be seen by
taqman analysis. Graph shows median and interquartile range data analysed using Kruskal-Wallis test. In donor 1 there is significant knockdown
for both SiRNA B and C in genes GSTCD, GPR176 and ETS1 (P < 0.01), in donor 2 only GSTCD reached statistical significance
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statistical significance and there was heterogeneity in the
data. Interestingly, the increase in apoptosis in cells
treated with GSTCD siRNA was more prominent in the
siRNA C treated cells which mirrored the more pro-
nounced effects of this siRNA on cell number. However,
we cannot exclude that other mechanisms are involved
but these data would provide some tentative support for
potential link to cell viability and apoptosis.
To provide greater insight into GSTCD function we
also completed transcriptomic analyses on primary
bronchial epithelial cells treated with two GSTCD
siRNA. In these analyses we focussed on genes identified
that are differentially expressed following knockdown in
both siRNA and across biological replicates which gave a
priority list of 17 genes (Table 2). The identification of
only 41 genes influenced by knockdown and then the
prioritisation to 17 highlights the potentially very limited
influence of GSTCD on global gene expression.
Lymphocyte cytosolic protein 1, LCP1 was the most sig-
nificantly reduced gene when GSTCD is reduced, this
gene has been identified by GWAS for non-alcoholic fatty
acid liver disease (NFALD) and mRNA from biopsies
show a 300% increase in mRNA in this disease compared
with control livers [26]. Similarly GPR176 a Gz-linked
orphan G-protein coupled receptor which represses
cAMP signalling in an agonist-independent manner in
the brain [27], had reduced levels which would
potentially have a significant effect on cell signalling
and is reduced when GSTCD is reduced. The top 6
genes altered by knockdown of GSTCD are also re-
duced included ETS1, a transcription factor for the
activation or repression of numerous genes involved
in stem cell development, cell senescence and death
and tumorigenesis [42, 43]. AKAP12 a protein which
directs the activity of protein kinase A by tethering
the enzyme near its physiologic substrates also has re-
duced expression, it has been shown to mediate bar-
rier functions in fibrotic scarring of the central
nervous system [44]. GPD1L a protein found in the
cytoplasm associated with the plasma membrane
where it binds to the sodium channel SCN5A is how-
ever upregulated with a reduction of GSTCD [45].
Interestingly, also in this list of priority genes were
genes already linked to respiratory disease including;
TGFBR1 and IL6R, two receptor linked to fibrosis
and inflammation in the airways respectively [33, 36]
see Table 3.
Gene set Enrichment Analysis (GSEA) identified eight
pathways that showed significant upregulation with no
pathways downregulated (Table 4). A number of these
pathways (Adipogenesis, Bile Acid metabolism and Fatty
acid metabolism) are involved in fat emulsification, me-
tabolism, storage and removal. The finding that when
GSTCD is targeted there are alterations in multiple
Fig. 7 Shows the results of the ROS assay in both fresh and frozen cells and supernatants. No difference was observed in ROS accumulation
between the Untransfected, scrambled, GSTCD SiRNA B or C in any of the condition which were: Fresh - Fresh supernatant, Homog – Fresh
homogenised cells, Frozen1 and 2 - supernatants stored at -80 °C. This is n = 1 from one biological experiment using different cell compartments
and conditions for ROS detection
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genes related to adipogenesis (confirmed by both siRNA)
is of interest as GSTCD−/− mice have been shown to
have abnormal body fat amount (International Mouse
Phenotyping Consortium). The link between adipose tis-
sue and chronic lung disease is unclear at this time,
however there is accumulating evidence for a causative
role including adipocyte derived mediators such as leptin
in obstructive lung disease and a link between cardiovas-
cular disease and COPD [46]. Again in the GSTCD−/−
mice there was abnormal electrocardiogram measure-
ment providing a cardiovascular connection in vivo.
The Reactive oxygen species (ROS) pathway being
highlighted in the RNA-seq pathway analyses is also of
interest with respect to lung disease as Asthma and
COPD are characterized by systemic and chronic local-
ized inflammation and oxidative stress. Sources of oxida-
tive stress arise from the increased burden of inhaled
oxidants, as well as elevated amounts of ROS released
from inflammatory cells. Increased levels of ROS, either
directly or via the formation of lipid peroxidation prod-
ucts may play a role in enhancing the inflammatory re-
sponse in both asthma and COPD (Oxidative stress in
asthma and COPD). To specifically address the potential
role of GSTCD in ROS pathways again we targeted
GSTCD using siRNA, however we were unable to iden-
tify a significant effect.
Conclusion
In conclusion, we provide new insight into the largely
uncharacterised protein, GSTCD that is a candidate gene
for lung function/COPD. GSTCD has no classical GST
activity and protein structure analyses suggest methyl-
transferase homology. Reduction of GSTCD expression
in bronchial epithelial cells by siRNA suggests a role in
cell viability. Transcriptomic analyses post GSTCD re-
duction identified several genes and pathways that may
be functionally relevant for the role of GSTCD including
genes in pathways implicated in fibrosis and inflamma-
tion in the airways. Pathway based approaches identified
a role for GSTCD particularly in adipogenesis which
complements well GSTCD−/− mouse data and warrants
further investigation for the potential causative role be-
tween GSTCD expression, adipose tissue inflammation
and COPD where data already exists for a potential
causative link.
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